Lexeo Therapeutics

Lexeo is attending the 6th Zurich International Symposium on arrhythmogenic cardiomyopathies. This premier event brings together leading experts to discuss the latest advancements in the diagnosis and treatment of arrhythmogenic cardiomyopathy, also known as ACM or ARVC. Lexeo is proud to sponsor this symposium, furthering our commitment to innovation and excellence in cardiology. We look forward to engaging with the global medical community to advance care for those affected by ACM.

Recently, our CEO Nolan Townsend spoke with Adam Bryant and Rhonda Morris for the 'Leading in the B-Suite' newsletter. He shared the experiences that have shaped his career trajectory, his journey to becoming CEO of a biopharmaceutical company, and his guidance for other African American leaders and professionals who aspire to be entrepreneurs. To read the full interview with Nolan, click here: https://lnkd.in/eV-gQn8y

Today we are highlighting Peter Janki, Manager, Nonclinical Bioanalystical Development as a valued member of our Lexeo team. Below, you'll find more about Peter's journey, his inspirations, and his contributions to our mission. We appreciate his dedication and passion for making a difference in #biotech. Check out his story below! #OneLexeo

We are looking forward to joining the world's leading cardiology experts at the European Society of Cardiology (ESC) Congress in London this weekend discussing personalized cardiology care and our improved understanding of underlying disease causes. Excited to connect and exchange ideas where ground-breaking research, pioneering technologies, and collaborative initiatives come together to transform patient care and shape the future of cardiovascular medicine.

The European Commission recently granted orphan medicinal product designation to LX2006 for the treatment of Friedreich ataxia (FA).       This milestone reinforces our belief our investigational gene therapy, LX2006, has the potential to be transformative for people with FA. FA cardiomyopathy is a serious and life-threatening condition with no approved therapies. We look forward to working closely with the European Medicines Agency and other regulatory agencies to expedite our clinical development and delivering this therapy to patients across the globe. 

Our Lexeo team recently enjoyed an amazing summer event that truly captured the spirit of #OneLexeo. We kicked off the day with a memorable cruise around New York City, taking in the stunning skyline and creating wonderful memories together. But the celebrations didn't stop there! We also marked a significant milestone – our two-year anniversary at the 345 Park Avenue office. This special event brought together colleagues, office neighbors like Apertura Gene Therapy, along with various vendors and friends of Lexeo for a fantastic evening of camaraderie and celebration. A huge thank you to everyone who joined us and made these events unforgettable. Your dedication and collaboration are what make Lexeo such a special place to work. Check out the team photo from our NYC cruise below! PC: Christopher Ruetten

We're excited to highlight a recent paper in the European Heart Journal on the genetics of hypertrophic cardiomyopathy (HCM). The study reveals that pathogenic variations in cardiac sarcomere genes account for 30%-40% of HCM cases. This paper speaks to the importance of genetic testing to understand the underlying cause of the disease, diagnostic confirmation, and future family planning. Discover more here: https://lnkd.in/gw8Y7ZWn

Did you know arrhythmogenic cardiomyopathy, or ACM (also known as ARVC), is a heart disease where heart muscle is replaced by fibrotic tissue and fatty deposits? This can lead to heart dysfunction and abnormalities in cardiac rhythm. Half of the estimated 130,000 people living with ACM in the US have a genetic underlying cause. A mutation/pathogenic variant in the PKP2 gene is the most common genetic driver of ACM, affecting about 60,000 people, although mutations in other genes can cause ACM as well. To date, there are no approved therapies that address the underlying genetic cause of ACM. Lexeo's investigational gene therapy, LX2020, is currently being evaluated in a phase 1/2 clinical trial called HEROIC-PKP2 for PKP2-ACM. Learn more about LX2020, Lexeo’s gene therapy candidate for PKP2-ACM: https://lnkd.in/gNWDX9aQ

Today, we are pleased to share our second quarter 2024 financial results and recent corporate updates.   Visit our ‘News & Events’ page to learn more about our latest progress. https://lnkd.in/eBcSeAaq

Friedreich ataxia (FA) is a genetic disease that is caused by deficiency in the frataxin protein. Symptoms typically begin in childhood and impact the nervous system (such as impaired muscle coordination, movement issues) and the heart. As the disease progresses, most patients develop heart conditions such as hypertrophic cardiomyopathy and arrhythmias. Although cardiac complications are the leading cause of death in almost 2/3 of patients with FA, there is currently no approved treatment for the heart problems associated with FA. At Lexeo, we are developing LX2006 to address this significant unmet need to address these critical cardiac manifestations: https://lnkd.in/exYWF9U7